These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 39026507)

  • 1. Anabolic treatment for osteoporosis and fragility fracture risk: one year in review 2024.
    De Mattia G; Maffi M; Mazzantini M
    Clin Exp Rheumatol; 2024 Jul; 42(7):1311-1316. PubMed ID: 39026507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
    McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA
    Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abaloparatide and the Spine: A Narrative Review.
    Thompson JC; Wanderman N; Anderson PA; Freedman BA
    Clin Interv Aging; 2020; 15():1023-1033. PubMed ID: 32636617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis.
    Chew CK; Clarke BL
    Maturitas; 2017 Mar; 97():53-60. PubMed ID: 28159062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis.
    Miller PD; Bilezikian JP; Fitzpatrick LA; Mitlak B; McCloskey EV; Cosman F; Bone HG
    Curr Med Res Opin; 2020 Nov; 36(11):1861-1872. PubMed ID: 32969719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of bone fragility in patients with diabetes: antiresorptive versus anabolic?
    Shah M; Appuswamy AV; Rao SD; Dhaliwal R
    Curr Opin Endocrinol Diabetes Obes; 2021 Aug; 28(4):377-382. PubMed ID: 34010225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of anabolic agents in the treatment of osteoporosis: a clinical update.
    Inderjeeth CA; Inderjeeth DC
    Curr Opin Endocrinol Diabetes Obes; 2024 Aug; 31(4):157-163. PubMed ID: 38752851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis.
    McClung MR; Harvey NC; Fitzpatrick LA; Miller PD; Hattersley G; Wang Y; Cosman F
    Menopause; 2018 Jul; 25(7):767-771. PubMed ID: 29462094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abaloparatide: A review of preclinical and clinical studies.
    Brent MB
    Eur J Pharmacol; 2021 Oct; 909():174409. PubMed ID: 34364879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy.
    Leder BZ
    Curr Osteoporos Rep; 2017 Apr; 15(2):110-119. PubMed ID: 28303448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis.
    Watts NB; Hattersley G; Fitzpatrick LA; Wang Y; Williams GC; Miller PD; Cosman F
    Osteoporos Int; 2019 Jun; 30(6):1187-1194. PubMed ID: 30899994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abaloparatide for the treatment of postmenopausal osteoporosis.
    Pietrogrande L; Raimondo E
    Drugs Today (Barc); 2018 May; 54(5):293-303. PubMed ID: 29911694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One year in review 2018: progress in osteoporosis treatment.
    Figliomeni A; Signorini V; Mazzantini M
    Clin Exp Rheumatol; 2018; 36(6):948-958. PubMed ID: 30526765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of osteoporosis medications on fracture healing.
    Hegde V; Jo JE; Andreopoulou P; Lane JM
    Osteoporos Int; 2016 Mar; 27(3):861-871. PubMed ID: 26419471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging anabolic agents in the treatment of osteoporosis.
    Lovato C; Lewiecki EM
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):247-257. PubMed ID: 28756709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide.
    Bhattacharyya S; Pal S; Chattopadhyay N
    Biochem Pharmacol; 2019 Aug; 166():185-191. PubMed ID: 31136739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.
    Bilezikian JP; Hattersley G; Fitzpatrick LA; Harris AG; Shevroja E; Banks K; Leder BZ; Zanchetta JR; Hans D
    Osteoporos Int; 2018 Feb; 29(2):323-328. PubMed ID: 29167971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?
    Miller PD; Derman RJ
    Osteoporos Int; 2010 Nov; 21(11):1793-802. PubMed ID: 20309524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoporosis Diagnosis, Management, and Referral Practice After Fragility Fractures.
    Snodgrass P; Zou A; Gruntmanis U; Gitajn IL
    Curr Osteoporos Rep; 2022 Jun; 20(3):163-169. PubMed ID: 35442009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.